Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. - Liu, Xinxue; Shaw, Robert H; Stuart, Arabella S V; Greenland, Melanie; Aley, Parvinder K; Andrews, Nick J; Cameron, J Claire; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Dinesh, Tanya; England, Anna; et al. (Lancet, 2021)